Mabpharm Limited (HK:2181) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Mabpharm Limited has announced that their biologic drug, CMAB008 (infliximab for injection), has received approval from the Ministry of Health of Peru for treating six inflammatory conditions, including ulcerative colitis and rheumatoid arthritis. CMAB008 is the first infliximab developed and approved in China, promising better affinity and longer lasting effects compared to existing anti-TNF drugs, and it is now covered by China’s medical insurance program. This approval marks a significant milestone for the company, potentially offering a more cost-effective treatment option for patients.
For further insights into HK:2181 stock, check out TipRanks’ Stock Analysis page.